Author:
Silver Nicholas,Paynter Mary,McAllister Georgina,Atchley Maureen,Sayir Christine,Short John,Winner Dane,Alouani David J.,Sharkey Freddie H.,Bergefall Kicki,Templeton Kate,Carrington David,Quiñones-Mateu Miguel E.
Funder
National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Virology,Molecular Medicine
Reference85 articles.
1. PHE. Public Health England—HIV in the United Kingdom: 2016 Report.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/602942/HIV_in_the_UK_report.pdf
. 2016.
2. O’Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4(7):e295–302.
3. Cunningham E, Chan YT, Aghaizu A, Bibby DF, Murphy G, Tosswill J, et al. Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. J Antimicrob Chemother. 2017;72(1):227–34.
4. Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, et al. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med. 2017;18(3):204–13.
5. U.K. HIV Drug Resistance Database.
http://www.hivrdb.org.uk
.